Capreomycin
The injectable peptide that fell out of favour for drug-resistant tuberculosis
Capreomycin is a cyclic polypeptide antibiotic from Streptomyces bacteria, given by injection for multidrug-resistant tuberculosis. Approved in the US as Capastat in 1971 and now discontinued, it was a standard part of resistant-TB regimens until a large analysis linked it to worse outcomes.
Used in human trials: 750 mg, Once daily, Intramuscular (Case report: XDR-TB in India) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
Work out syringe units → · New to syringes? · All dosing data ↓
What is it?
Capreomycin was for decades one of the injectable drugs used in combination regimens for multidrug-resistant tuberculosis (MDR-TB). It binds the bacterial ribosome and blocks protein synthesis. It had to be injected repeatedly for months, and like the aminoglycosides it is associated with kidney damage and hearing loss. It also disturbs blood salts: early reports described low potassium, magnesium and calcium in patients treated with it.
The evidence turned against it. A 2021 individual-patient meta-analysis of injectables in MDR-TB found capreomycin had been given to more patients than amikacin despite worse results: compared with capreomycin, amikacin was associated with 9 more cures and 5 fewer deaths per 100 patients treated, and streptomycin with 10 more cures and 10 fewer deaths.
Resistance was a second problem. In South African patients with extensively drug-resistant TB, nearly nine in ten carried capreomycin-resistance mutations, mostly the rrs A1401G change, yet almost all were given it anyway, and resistance lowered the odds that their sputum cleared. Structural studies show its ribosome binding pocket depends on a distant rRNA methylation, and mutations in the rrs gene and in tlyA are known to confer resistance.
Its salt-wasting effect was not trivial. In an Indonesian cohort, potassium ran lower on capreomycin than kanamycin regimens and more patients were hospitalised or switched for electrolyte problems, and a case report describes tetany that only resolved once magnesium was corrected.
In a 2017 UK cohort, hearing loss was about five times more likely with amikacin than with capreomycin alone, and kidney injury was more frequent when injectables were combined with antiretroviral therapy in people with HIV, a reminder that both injectables carried real toxicity. In the US, Capastat is listed as discontinued. Researchers have explored inhaled capreomycin powders to reduce systemic toxicity, but none is approved.
Mechanism of Action
Capreomycin is a cyclic polypeptide antibiotic that binds the bacterial ribosome at the subunit interface and blocks protein synthesis.
Ribosome binding
Binds where the two ribosome subunits meet, in a pocket pre-shaped by a distant rRNA methylation.
Resistance
rrs A1401G mutations and loss of tlyA function confer resistance and cross-resistance with other injectables.
Salt wasting
Causes loss of potassium, magnesium and calcium; magnesium must be corrected for the others to recover.
Published Research
Studies of capreomycin, from their PubMed abstracts.
Individual-patient meta-analysis of injectables
Across MDR-TB patients given injectables, capreomycin (2,401 patients) was used more than amikacin despite worse results: compared with capreomycin, amikacin was associated with 9 more cures and 5 fewer deaths per 100 patients, and streptomycin with 10 more cures and 10 fewer deaths.
Electrolyte disturbances
Tuberculosis patients treated with capreomycin developed gross electrolyte disturbances, including low potassium, magnesium and calcium and alkalosis, probably through secondary hyperaldosteronism; the authors advised withdrawing the drug if these developed.
Kidney injury with tenofovir
In 215 South African patients with drug-resistant TB on kanamycin- or capreomycin-based regimens, nephrotoxicity ran at 3.6 cases per 100 person-months without antiretrovirals and 6.9 with tenofovir (hazard ratio 2.06, not significant), and 12 with other antiretrovirals (HR 4.09).
Adverse-event reports
In the WHO VigiAccess database, reports for capreomycin rose for weakness and hearing loss, alongside the hearing loss and gastrointestinal effects reported with kanamycin; spontaneous reports cannot give rates.
XDR-TB in South Africa: mostly resistant
Of 178 patients with extensively drug-resistant TB, 87% had capreomycin-resistance mutations (mostly rrs A1401G), yet 92% were treated with it; resistance lowered the odds of sputum conversion.
KwaZulu-Natal: primary resistance
Among 52 XDR-TB patients with full susceptibility testing, 90.4% were capreomycin-resistant, mostly in one clustered strain lineage; resistant patients did worse, though not significantly.
Electrolytes: capreomycin vs kanamycin
In 84 MDR-TB patients in Indonesia, serum potassium was lower on capreomycin than kanamycin regimens (3.2 against 3.7 mEq/L), with more hospitalisations and regimen changes for electrolyte imbalance.
Tetany on treatment
A woman with XDR-TB on 750 mg daily developed low potassium at 7 weeks that resisted replacement, then tetany with low calcium and magnesium at 12 weeks; correcting magnesium restored the other salts.
Ear and kidney harm: amikacin vs capreomycin
In 47 MDR-TB patients, 34% developed ototoxicity, more often on amikacin, and 27.7% nephrotoxicity, linked to earlier kidney impairment; mitochondrial DNA variants did not explain who was affected.
Global adverse-event reports
In WHO's VigiBase, deafness reports were most disproportionately linked to amikacin and kanamycin, while vertigo was reported less often with capreomycin.
Pharmacokinetic model
An exploratory physiologically based pharmacokinetic model of capreomycin, a cyclic peptide antibiotic often grouped with the aminoglycosides, was built from targeted experimental data to predict its absorption, distribution and excretion.
Capreomycin vs amikacin side effects
In 100 UK patients, 55% had ototoxicity and 40% stopped the injectable for hearing loss; ototoxicity was about five times more likely in those started on amikacin than in those on capreomycin only.
Inhaled capreomycin powder
A spray-dried inhaled powder of capreomycin was developed to target the lungs and reduce the systemic toxicity of repeated injections five times a week; it has not reached approval.
Cross-resistance with other injectables
Analysis of resistant M. tuberculosis linked mutations in the 16S rRNA gene (rrs) and in tlyA to resistance to capreomycin, kanamycin, amikacin and viomycin, explaining variable cross-resistance among these injectables.
How the ribosome holds it
Structural work showed that methylation of a distant 23S rRNA nucleotide pre-shapes capreomycin's binding pocket at the ribosome subunit interface, making the drug's binding depend on that modification.
Dosing Data
There is no current US product. It was given by daily intramuscular injection for months as part of MDR-TB regimens; one case report describes 750 mg a day.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Capreomycin is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
An arithmetic example, not a recommendation: a 10 mg vial mixed with 3 mL of bacteriostatic water holds 3,333.3 mcg per mL, so 750 mg, the “Case report: XDR-TB in India” row would be 22500.0 units, more than a 1 mL U-100 syringe holds. Put your own vial's numbers into the reconstitution calculator.
Source: dose: Used in human trials, PMID 31562727 (Dosing Data below); vial and water: the calculator's default example, not a vial size we have a source for.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Capreomycin, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Capreomycin stays intact once mixed.
How it is taken
As it was given in human studies: Intramuscular (Once daily; Case report: XDR-TB in India).
For injection technique, sites and needle disposal, see the mixing guide.
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Case report: XDR-TB in India: Months (tetany at 12 weeks).
When effects appear: unknown; no source on this page gives a time to effect for Capreomycin. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Hearing loss and kidney toxicity, as with other injectable anti-TB drugs; Months of repeated injections. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Capreomycin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
Unknown: a PubMed search for human interaction studies of Capreomycin (reviewed 2026-10-05) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Capreomycin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Discontinued (Approved in the US as Capastat, NDA 050095, on June 2, 1971). Sport: Unsettled (S0 may apply).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
No current US label: the product is discontinued and DailyMed has no manufacturer label (read October 3, 2026).
Legal Status
Capreomycin is no longer marketed in the US.
Frequently Asked Questions
?Is capreomycin a peptide?
Yes. It is a cyclic polypeptide antibiotic produced by Streptomyces bacteria.
?Is capreomycin still used for tuberculosis?
It is discontinued in the US, and a 2021 individual-patient meta-analysis found capreomycin was associated with fewer cures and more deaths than amikacin or streptomycin.
?What are capreomycin's side effects?
Like other injectable TB drugs it can cause hearing loss and kidney damage; in a UK cohort, 40% of patients stopped their injectable because of hearing loss.
References
- [fda] US FDA, Drugs@FDA (openFDA): CAPASTAT, NDA 050095 (June 2, 1971), marketing status discontinued; no manufacturer label on DailyMed. Read October 3, 2026.
- [pubmed] Arnold A, et al. "Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis." Antimicrob Agents Chemother, 2017;61(9). PMID: 28696239.
- [pubmed] Shao Z, et al. "Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy." Pharmaceutics, 2021;13(12). PMID: 34959328.
- [pubmed] Maus CE, et al. "Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis." Antimicrob Agents Chemother, 2005;49(8):3192-7. PMID: 16048924.
- [clinical-trial] Cegielski JP, et al. "Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016." Clin Infect Dis, 2021;73(11):e3929-e3936. PMID: 33124668.
- [pubmed] Holmes AM, et al. "Capreomycin-induced serum electrolyte abnormalities." Thorax, 1970;25(5):608-11. PMID: 5489186.
- [pubmed] Reisfeld B, et al. "A physiologically based pharmacokinetic model for capreomycin." Antimicrob Agents Chemother, 2012;56(2):926-34. PMID: 22143528.
- [pubmed] Perumal R, et al. "Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy." J Acquir Immune Defic Syndr, 2018;78(5):536-542. PMID: 29683992.
- [pubmed] Singh L, et al. "Adverse effects associated with Kanamycin, Amikacin, Capreomycin and Bedaquiline -a VigiAccess™ study." Afr Health Sci, 2024;24(2):62-70. PMID: 40809576.
- [pubmed] Pietersen E, et al. "High frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosis." PLoS One, 2015;10(4):e0123655. PMID: 25909847.
- [pubmed] OʼDonnell MR, et al. "Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa." J Acquir Immune Defic Syndr, 2015;69(5):536-43. PMID: 25886924.
- [pubmed] Soeroto AY, et al. "Comparison of Serum Potassium, MagnEsium, and Calcium Levels between Kanamycin and Capreomycin-BASEd Regimen-Treated MultiDrug-Resistant TuBerculosis Patients in Bandung (CEASE MDR-TB): A Retrospective Cohort Study." Int J Microbiol, 2019;2019:5065847. PMID: 31001341.
- [pubmed] Puri MM, et al. "Tetany in an Extensively Drug Resistant Tuberculosis (XDR-TB) Patient Treated with Capreomycin." J Assoc Physicians India, 2019;67(8):79-82. PMID: 31562727.
- [pubmed] Freimane L, et al. "Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors." J Pers Med, 2023;13(4). PMID: 37108985.
- [pubmed] Sagwa EL, et al. "Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment." Pharmacoepidemiol Drug Saf, 2017;26(1):1-8. PMID: 27868278.
- [pubmed] Nandi S, et al. "Distant ribose 2'-O-methylation of 23S rRNA helix 69 pre-orders the capreomycin drug binding pocket at the ribosome subunit interface." Nucleic Acids Res, 2025;53(13). PMID: 40626557.
Sources & Citations
Studies were read from their PubMed abstracts; DailyMed has no capreomycin label. Read October 7, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.